A Potential Boost for Antidepressant Efficacy
Creatine supplementation may offer a new avenue for treating major depressive disorder in women, according to research recently published in the Canadian Journal of Psychiatry. The findings suggest the supplement acts not as a standalone cure, but as a potential adjunct to traditional antidepressants or cognitive behavioral therapy. Still, medical experts caution that findings remain inconsistent, and the data is not yet robust enough to warrant a standard clinical recommendation.
The Data Behind Sex-Specific Results
The review scrutinized five randomized controlled trials comprising 238 participants, with an average age of 36. The results point toward sex-specific efficacy. One trial found that women taking five grams of creatine daily alongside the antidepressant escitalopram saw a more significant reduction in symptoms over eight weeks than those on a placebo. A second trial, which included both men and women undergoing cognitive behavioral therapy, found that adding creatine yielded greater improvements in depression scores.
Nicholas Fabiano, MD, a resident in the Department of Psychiatry at the University of Ottawa and study co-author, suggests a biological explanation. Because women often hold lower baseline creatine stores, including in specific brain regions, they may be uniquely responsive to supplementation.
Fueling Brain Cell Metabolism
While long associated with muscle energy, creatine’s role in cerebral function is gaining traction. The supplement supports the production of adenosine triphosphate (ATP), the primary energy currency for cellular function. “ATP is essentially the fuel our brain cells use to function,” explains Thea Gallagher, PsyD, a clinical associate professor at NYU Langone Health. By increasing ATP availability, creatine may help brain cells function more effectively, potentially aiding mood regulation. Hillary Ammon, PsyD, of the Center for Anxiety and Women’s Emotional Wellness, adds that this metabolic boost could provide a necessary supportive mechanism for those already in primary treatment.
Statistically Inconsistent Outcomes
The research is far from conclusive. In fact, three of the five trials analyzed showed no statistically significant benefit. These broader, more diverse studies included teenagers, treatment-resistant individuals, and patients diagnosed with bipolar disorder.
Safety remains a hurdle. In the study involving bipolar patients, two individuals experienced episodes of mania or hypomania after taking the supplement. Dr. Gallagher cautions against overstating these preliminary findings, emphasizing that the current body of evidence relies on small sample sizes.
There is no established clinical consensus on dosage, with trials testing amounts ranging from two to 10 grams daily. Because the research remains in its infancy, medical professionals emphasize that creatine is not a replacement for standard psychiatric care. Instead, it is being explored as a potential “tool in the toolbox” for patients requiring additional support. Patients should consult their healthcare provider before beginning any regimen to monitor for side effects and potential medication interactions.